tiprankstipranks
Advertisement
Advertisement
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
PremiumCompany AnnouncementsImmuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
27d ago
Immuneering announces updated data from Phase 2a trial for atebimetinib
Premium
The Fly
Immuneering announces updated data from Phase 2a trial for atebimetinib
1M ago
Immuneering announces presentation of new genetic data at 2026 AACR
Premium
The Fly
Immuneering announces presentation of new genetic data at 2026 AACR
1M ago
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
PremiumRatingsAdvancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
3M ago
Midday Fly By: Rising oil prices, falling employment sink stocks
Premium
The Fly
Midday Fly By: Rising oil prices, falling employment sink stocks
3M ago
Immuneering reports Q4 EPS (18), consensus (31c)
Premium
The Fly
Immuneering reports Q4 EPS (18), consensus (31c)
3M ago
Closing Bell Movers: Defense stocks surge on Trump military budget comments
PremiumThe FlyClosing Bell Movers: Defense stocks surge on Trump military budget comments
5M ago
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
Premium
The Fly
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
5M ago
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
Premium
Company Announcements
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100